Journal Scans
Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
Better Chemotherapy and Liver Resection Improve Metastatic CRC Survival
S Kopetz, G Chang, M Overman, C Eng, D Sargent, D Larson, A Grothey, J Vauthey, D Nagorney, R McWilliams
20090426
2009 May 26
J Clin Oncol
Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
J Clin Oncol. 2009 May 26; Epub ahead of print, S Kopetz, G Chang, M Overman, C Eng, D Sargent, D Larson, A Grothey, J Vauthey, D Nagorney, R McWilliams
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
The overall survival (OS) of patients with metastatic colorectal cancer (CRC) has improved over the years as new drugs and new surgical techniques have become available. Initially, when fluorouracil (FU) and leucovorin were used alone for treating patients with metastatic colon cancer, survival was limited to 8 to 12 months. Newer drugs, including irinotecan, oxaliplatin, capecitabine, bevacizumab, cetuximab, and panitumumab, have increased the treatment options for these patients. Recent phase III...
